Cytovac performs in house research, GMP production, Clinical trials and Quality management. Clinical trials are performed in close collaboration with leading Scandinavian hospitals and doctors. The company employs a dedicated staff that has research experience within immunology and cell biology, together with expertise within the fields of clinical research, pharmaceutical production and quality control.
The culture at CytoVac is open, forthcoming and professionally well-founded. All the employees are dedicated to the purpose of developing gentle and efficient ways to treat cancer.
Cytovac A/S was founded in 2008 by Bent Alsø, Dr. Alexei Kirkin and Dr. Karine Dzhandzhougazyan. The technology behind the ALECSAT therapy is based on Dr. Kirkin and Dr. Dzhandzhougazyan’s basic research. The company is financed by private investors.
Parts of the scientific basis for this immunotherapy was initially developed in collaboration with the Danish Cancer Society, supported by private foundations. The Cancer Society is still a close collaboration partner.
In 2007, Dr. Karine Dzhandzhugazyan and Dr. Alexei Kirkin obtained the first patents for protection of the ALECSAT technology that is fully owned by CytoVac. The patent portfolio has continuously expanded since then.
The Interim Report Q1 2019 is now ready in English and in Swedish